IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Hiroaki ITO et al.

Title

A PREVENTIVE OR

THERAPEUTIC AGENT FOR INFLAMMATORY BOWEL DISEASE COMPRISING IL-6 ANTAGONIST AS AN ACTIVE

INGREDIENT 10/677.227

Appl. No.:

Filing Date: 10/3/2003

Examiner:

Prema Maria MERTZ

Art Unit:

1646

Confirmation 8597

Number:

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR \$1.56

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir

Submitted herewith on Form PTO/SB/08 is a listing of a document known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR \$1.56.

A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present

application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a prima facie art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed document is being submitted in compliance with 37 CFR §1.97(c), before the mailing date of either a final action under 37 CFR §1.113, a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application.

RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP \$609.

FEE

Fees in the amount of \$180,00 in accordance with 37 CFR §1.17(p) to cover the fee associated with an information disclosure statement under 37 CFR §1.97(c) are being paid by credit card via EFS-Web.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by the credit

eard payment instructions in EFS-Web being incorrect or absent, resulting in a rejected or incorrect credit card transaction, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Stephen B. Maebius Attorney for Applicant

Registration No. 35,264

7.4

FOLEW& LARDNER LLP Customer Number: 22428 Telephone: (202) 672-5569 Facsimile: (202) 672-5399

HCW/SBM/ARSC:kdm

Attachment: Form PTO/SB/08

Approved for use through 03/31/2007, OMG 0651-9031

U.S. Patent and Trademark Office. U.S. DEPARTMENT OF COMMERCE.
Under the Papermark Reduction Act of 1995, no persons are required to respond to a collection of information unless a postagra a valid OMB control.

	Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Oate Submitted: June 1, 2007			Complete if Known		
				Application Number	10/677,227	
				Filing Date	10/3/2003	
				First Named Inventor	Hisroski ITO	
				Ast Unit	1646	
(use as many sheets as necessary)			cessaryi	Examiner Name	Prema Mario MERTZ	
Sheet	1	of	1	Attorney Docket Number	053486-0385	

			U.S. PATENT DO		
Examiner Indials*	Cae No	Document Number Number Kind Code ² (#wown)	Publication Date MM-QQ-YYYY	Name of Palentee or Applicant of Cred Document	Pages, Calumns, Lines, Where Resevers Passages or Relevent Figures Appear
				•	

		2			

UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS				
Examinar C4e U.S.Patent Application Examinar C4e Document Initiats* No Serial Number Kind Code* or Research	Filing Date of Clied Document MM-OD-YYYY	Name of Patentee or Applicant of Clied Document	Pages, Columns, Unes, Where Relevant Passages or Relevant Figures Appear	

			FOREIGN PATENT D	OCUMENTS		
Examine: Initials*	Cite No.1	Foreign Patent Document Country Code Number Kind Code' (#kneum)	Publication Date 1864-00-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Courris, Lines. Where Rolevani. Passages or Resevent Figures Appear	140
					Ł	

Examiner Initials*	Cite Include name of the author (in CAPTAS, LETTERS), tills of the article (when appropriate), tills of the No item (leook, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	HARRISON, Paul, et. al., Inhibition of the acute-phase response in vivo by anti-gp130 monoclonal entitodies, Editor Journal of Hearnatoropy, 1996, pp. 443-451, Vol. 95, Blackwell Science Ltd., Oklahoma City, Oklahoma, User	

Examiner	Date
Signature	Considered
*EXAMBLE 9000 Following considered, whether arried contains a in conformance with MFEP 609. Dra	

"EXAMINES In this is finite-room composined, whether or not collations are construences with MREPF GET. Draw here through collation is an operational control of the control of the collection o

The control of the co